Terence W. Friedlander
0000-0002-3630-4941
Publication & Citation Trends
Publications
0 total
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Cited by 0
Semantic Scholar
Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa).
Cited by 0
Semantic Scholar
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Cited by 6
Semantic Scholar
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
Cited by 5
Semantic Scholar
Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.
Cited by 0
Semantic Scholar
Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.
Cited by 1
Semantic Scholar
A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).
Cited by 4
Semantic Scholar
A phase 2, open-label, randomized study of livmoniplimab in combination with budigalimab versus chemotherapy in patients with metastatic urothelial carcinoma.
Cited by 0
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(144)
Bladder and Urothelial Cancer Treatments
(141)
Cancer Immunotherapy and Biomarkers
(119)
Urinary and Genital Oncology Studies
(65)
Multiple Myeloma Research and Treatments
(35)
Affiliations
Fox Chase Cancer Center
Roswell Park Comprehensive Cancer Center
San Francisco General Hospital
Cleveland Clinic
Janssen (Belgium)